ClinicalTrials.gg
Enrolling by invitationNCT06929897POBI-PFAUpdated Jul 16, 2026

PVI Alone vs PVI With Posterior Wall Isolation for Pulse-Field Ablation in Persistent AF

An interventional study of Pulmonary Vein Isolation and Additional Left Atrial Posterior Wall Ablation in Atrial Fibrillation (AF), sponsored by Ewha Womans University Mokdong Hospital. Enrolling by invitation at 1 site in South Korea. Open to participants aged 20 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by Ewha Womans University Mokdong Hospital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
482
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 209 studies in Atrial Fibrillation with a site in Korea, Republic of — 61 open to participants now, 69 under way, 2 of them phase 3. Atrial Fibrillation · Korea, Republic of.

Planned enrollment
51st of 144
482 · median 300
Started
2026
with 16 others
No phase
91 of 209
36 open now
Primary completion
2029-06
later than 50 of 68 live
Registered
172nd of 209
by date
Lead sponsor
8 of 209
Ewha Womans University Mokdong Hospital

Among the 209 studies in Atrial Fibrillation with a site in Korea, Republic of, this one is the 51st largest by planned enrollment of the 144 interventional ones that give a count, is one of 17 that started in 2026, is one of 91 with no phase, reaches primary completion later than 50 of the 68 other live ones, and was the 172nd registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

61 of the 209 studies in Atrial Fibrillation with a site in Korea, Republic of are open now. Recruiting first, the newest first:

56 more — sign in →

All 61 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 20 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 209 studies in Atrial Fibrillation with a site in Korea, Republic of, or all of them as a file.
02

Study summary

To date, no optimal treatment has been established to improve outcomes in patients with persistent atrial fibrillation. The safety and efficacy of pulsed-field ablation (PFA) have been demonstrated in several studies, and its clinical application is expanding.

- In patients with persistent atrial fibrillation, can the addition of posterior wall isolation (PWI) following pulmonary vein isolation (PVI) using PFA reduce recurrence?

Participants will:

  • Undergo either PVI alone or PVI with additional left atrial posterior wall isolation (PWI)
  • Visit the clinic to assess for recurrence of atrial tachyarrhythmias
Read the detailed description

Atrial fibrillation is a major cardiovascular disease, and catheter ablation has become an established rhythm-control strategy that provides superior outcomes compared with pharmacological therapy in patients with drug-refractory atrial fibrillation. Although the efficacy of pulmonary vein isolation (PVI) is well established in patients with paroxysmal atrial fibrillation, the effectiveness of additional ablation strategies beyond PVI remains uncertain in patients with persistent atrial fibrillation.

Several studies have suggested that left atrial posterior wall isolation (PWI) may help reduce recurrence; however, conventional thermal ablation techniques have been limited by technical challenges in achieving durable lesion formation. Pulsed field ablation (PFA) is a nonthermal ablation technology that creates selective myocardial lesions, enabling rapid and consistent lesion formation while minimizing injury to surrounding tissues.

This study aims to prospectively and randomly compare PVI alone using PFA with PVI followed by additional PWI in patients with persistent atrial fibrillation. By evaluating recurrence rates, procedure time, complications, atrial fibrillation burden, and patient satisfaction, this study seeks to identify the optimal ablation strategy for patients with persistent atrial fibrillation.

03

Conditions studied

  • Atrial Fibrillation (AF)

Browse trials for

Keywords

  • pulsed field ablation
  • catheter ablation
  • posterior wall isolation
  • atrial fibrillation
04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 20 to 80 years who are candidates for catheter ablation for persistent atrial fibrillation
  • Patients eligible for catheter ablation according to existing clinical guidelines
  • Those without structural heart disease (e.g., severe mitral regurgitation)
  • Those without to anticoagulation therapy

Exclusion criteria

Exclusion Criteria:

  • Atrial fibrillation associated with severe congenital heart disease or structural heart disease
  • Patients with to general anesthesia or sedation for the procedure
  • History of prior cardiac surgery (e.g., Maze procedure, coronary artery bypass grafting)
  • History of atrial fibrillation catheter ablation within the past 12 months
  • Patients with severe left ventricular dysfunction ( \<30%)
  • Patients with active internal bleeding
  • Patients with contraindications to anticoagulation therapy and antiarrhythmic drugs
  • Valvular atrial fibrillation (e.g., mitral stenosis > grade 2, mechanical valve, prior mitral valve repair)
  • Patients with severe comorbid conditions
  • Patients with an expected survival of less than one year
  • Patients with drug or alcohol addiction
  • Pregnant or breastfeeding women
  • Any other conditions deemed by the investigator to make the patient unsuitable for study participation
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
482 participants (estimated)

Study arms

  • Active comparator
    Additional Left Atrial Posterior Wall Ablation Group

    Pulmonary vein isolation (PVI) is performed as the primary procedure. After PVI, direct current (DC) cardioversion is performed to restore normal sinus rhythm. If the patient converts to sinus rhythm, they are randomly assigned to either the PVI-only group or the additional left atrial posterior wall ablation group. Patients who fail to convert to sinus rhythm after DC cardioversion are excluded from randomization. Patients assigned to this group after successful conversion to normal sinus rhythm by electrical cardioversion following PVI will undergo additional left atrial posterior wall isolation using pulsed field ablation. Before completion of the procedure, electrical isolation of both the pulmonary veins and the left atrial posterior wall will be confirmed. Thereafter, anticoagulation therapy and rhythm follow-up will be performed according to the study protocol.

    Procedure: Pulmonary Vein Isolation · Procedure: Additional Left Atrial Posterior Wall Ablation

  • Placebo comparator
    Pulmonary Vein Isolation (PVI) only Group

    Pulmonary vein isolation (PVI) is performed as the primary procedure. After PVI, direct current (DC) cardioversion is performed to restore normal sinus rhythm. If the patient converts to sinus rhythm, they are randomly assigned to either the PVI-only group or the additional left atrial posterior wall ablation group. Patients who fail to convert to sinus rhythm after DC cardioversion are excluded from randomization. Patients assigned to this group after successful conversion to normal sinus rhythm by electrical cardioversion following PVI will undergo no additional left atrial posterior wall isolation. Before completion of the procedure, electrical isolation of the pulmonary veins will be confirmed. Thereafter, anticoagulation therapy and rhythm follow-up will be performed according to the study protocol.

    Procedure: Pulmonary Vein Isolation · Procedure: Non-PV trigger test

Interventions

  • ProcedurePulmonary Vein Isolation

    1. Pulmonary vein isolation (PVI) is performed as the primary procedure. 2. After PVI, direct current (DC) cardioversion is performed to restore normal sinus rhythm. If the patient converts to sinus rhythm, they are randomly assigned to either the PVI-only group or the additional left atrial posterior wall ablation group. 3. Patients who fail to convert to sinus rhythm after DC cardioversion are excluded from randomization.

    Also known as: PVI

  • ProcedureAdditional Left Atrial Posterior Wall Ablation

    1. Additional left atrial posterior wall ablation is performed. 2. Complete electrical isolation of the entire left atrial posterior wall is confirmed (posterior box lesion isolation must be achieved). 3. Post-procedural rhythm monitoring follows the study protocol.

    Also known as: Posterior box isolation

  • ProcedureNon-PV trigger test

    1. If atrial fibrillation triggers are identified with isoproterenol infusion, additional focal ablation is performed. 2. Post-procedural rhythm monitoring follows the study protocol.

06

What researchers measure

Primary outcomes

  1. Recurrence of atrial tachyarrhythmia

    Freedom from documented AF/AT/AFL ≥30 seconds at 12 months post-procedure

    Time frame: Within 12 months after the procedure, excluding the first 4-week blanking period

Secondary outcomes

  1. Peri-procedural complication

    Major ; brain hemorrhage, thromboembolism , atrial -esophageal fistula, pericardial effusion, tamponade, irreversible phrenic nerve palsy, bleeding requiring transfusion, Pulmonary Vein Stenosis: Minor ; puncture site bleeding not requiring transfusion , groin hematoma, reversible phrenic nerve palsy

    Time frame: Within 12 months after the procedure

  2. Total procedure time

    total procedure time

    Time frame: Periprocedural

  3. Length of hospital stay

    Length of hospital stay

    Time frame: Within one year from the time of enrollment

  4. Atrial fibrillation burden assessed by Holter ECG

    Atrial fibrillation burden will be calculated as the percentage of the total analyzable Holter ECG monitoring time spent in atrial fibrillation or atrial tachyarrhythmia. Values range from 0% to 100%, with higher percentages indicating a greater atrial fibrillation burden and therefore a worse outcome.

    Time frame: Within 12 month from the time of enrollment

  5. patient satisfaction

    Atrial Fibrillation Effect on Quality-of-Life(AFEQT)

    Time frame: Within one year from the time of enrollment

07

Study locations

1 site
  • Ewha Womans University Mokdong Hospitoal
    Seoul, South Korea
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared due to concerns regarding patient confidentiality and the lack of specific consent for data sharing obtained during the study enrollment process.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jun 2029, 35 months after the start.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 35 months is below that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2025
First posted
Apr 16, 2025
StartActual
Jul 3, 2026
Primary completionEst.
Jun 30, 2029
CompletionEst.
Dec 31, 2029
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06929897
Lead sponsor
Ewha Womans University Mokdong Hospital
Collaborators
Ewha Womans University Seoul Hospital, Korea University Anam Hospital, Kangbuk Samsung Hospital, Asan Medical Center, Severance Hospital, Samsung Medical Center, Chonnam National University Hospital, Daegu Catholic University Medical Center
Responsible party
Sponsor
First posted
Apr 16, 2025
Start date
Jul 3, 2026
Primary completion
Jun 30, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Jul 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion